Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)

American Journal of Hematology

Volumn 90, Issue 3, 2015, Pages 204-207

  Quinquenel, Anne ^a,b   Willekens, Christophe ^c   Dupuis, Jehan ^d   Royer, Bruno ^e   Ysebaert, Loic ^f   Guibert, S De ^g   Michallet, Anne Sophie ^h   Feugier, Pierre ⁱ   Guieze, Romain ^j   Levy, Vincent ^k   Delmer, Alain ^a,b  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f IUCT Oncopole   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^k AVICENNE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENDAMUSTINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; PREDNISONE; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOPENIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; INFECTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SURVIVAL; TREATMENT RESPONSE; ANEMIA, HEMOLYTIC, AUTOIMMUNE; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84923116275     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23909     Document Type: Article

References (21)

1. Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: Prevalence, clinical associations, and prognostic significance. Blood 2010;116:4771-4776.
2. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141:615-621.
3. Galletti J, Canones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: Possible role as initiators of autoimmune hemolytic anemia. J Immunol 2008;181:3674-3683.
4. Hall AM, Vickers MA, McLeod E, et al. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105:2007-2015.
5. Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: A systematic review. Haematologica 2011;96:752-761.
6. Gribben JG. How I treat CLL up front. Blood 2010;115:187-197.
7. Kaufman M, Limaye SA, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:892-899.
8. Rossignol J, Michallet AS, Oberic L, et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011;25:473-478.
9. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209-3216.
10. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559-3566.
11. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
12. Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol 2014;89:1055-1062.
13. Vanura K, Le T, Esterbauer H, et al. Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica 2008;93:1912-1916.
14. Visco C, Giaretta I, Ruggeri M, et al. Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia. Leukemia 2007;21:1092-1093.
15. Glance LE, Cumpston A, Kanate A, et al. Bendamustine-associated hemolytic anemia. Ann Pharmacother 2009;43:1903-1906.
16. Goldschmidt N, Gural A, Ben-Yehuda D, et al. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia. Cancer Chemother Pharmacol 2013;72:709-713.
17. Haddad H, Mohammad F, Dai Q. Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature. Hematol Oncol Stem Cell Ther, in press.
18. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-4384.
19. Eichhorst B, Fink A-M, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the CLL10 trial, an International, Randomized Study Of The German CLL Study Group (GCLLSG). Blood 2013;122:526.
20. Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab-Incidence and predictors. Br J Haematol 2007;136:800-805.
21. Rogers K, Woyach J, Andritsos L, et al. Incidence of autoimmune cytopenias (AIC) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) patients (pts) treated with ibrutinib. Blood, Abstract 1997, ASH, December 2014.